Cross-source evidence timeline
Glepaglutide research timeline
Follow 9 selected, directly cited source records from December 22, 2017 through September 29, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT07197944↗
PeptideScanner retained ClinicalTrials.gov record NCT07197944 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT03905707↗
PeptideScanner retained ClinicalTrials.gov record NCT03905707 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT04881825↗
PeptideScanner retained ClinicalTrials.gov record NCT04881825 at 2026-11-16T01:46:56.290Z. Its registry update date was 2026-09-08, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026Literature metadata
Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS-1 phase 3 trial.↗
PubMed lists PMID 41816796 in Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, with publication-date metadata of 2026-03-12 (day precision). PeptideScanner associated the retained record with the identity slug glepaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 12, 2026 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT03690206↗
PeptideScanner retained ClinicalTrials.gov record NCT03690206 at 2026-11-16T01:46:56.290Z. Its registry update date was 2025-07-17, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT04991311↗
PeptideScanner retained ClinicalTrials.gov record NCT04991311 at 2026-11-16T01:46:56.290Z. Its registry update date was 2024-11-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026
Source year
2021
Clinical trials
ClinicalTrials.gov record NCT04318743↗
PeptideScanner retained ClinicalTrials.gov record NCT04318743 at 2026-11-16T01:46:56.290Z. Its registry update date was 2021-07-14, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT04178447↗
PeptideScanner retained ClinicalTrials.gov record NCT04178447 at 2026-11-16T01:46:56.290Z. Its registry update date was 2020-11-18, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT03279302↗
PeptideScanner retained ClinicalTrials.gov record NCT03279302 at 2026-11-16T01:46:56.290Z. Its registry update date was 2017-12-22, and PeptideScanner's reviewed identity mapping was glepaglutide.↗
Added to PeptideScanner November 16, 2026